MGMT Promotor Methylation is a strong prognostic biomarker for benefit from dose-intensified Temozolomide rechallenge in progressive Glioblastoma: The DIRECTOR Trail.

Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Studiy Group

Clin Cancer Res 2015;21: 2057 – 2064